vs
中国太平保险控股（IGIC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
中国太平保险控股的季度营收约是Orthofix Medical Inc.的1.8倍（$403.8M vs $219.9M），中国太平保险控股净利率更高（26.0% vs -1.0%，领先27.0%）
中国太平保险控股有限公司（前身为中国保险国际控股有限公司）是一家中国保险集团，虽在香港注册成立，但背靠中国中央政府，属红筹企业，在保险行业拥有深厚的资源积累与市场影响力。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
IGIC vs OFIX — 直观对比
营收规模更大
IGIC
是对方的1.8倍
$219.9M
净利率更高
IGIC
高出27.0%
-1.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $403.8M | $219.9M |
| 净利润 | $105.1M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 26.0% | -1.0% |
| 营收同比 | — | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $2.31 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IGICOFIX
| Q4 25 | — | $219.9M | ||
| Q3 25 | $403.8M | $205.6M | ||
| Q2 25 | $261.9M | $203.1M | ||
| Q1 25 | — | $193.6M | ||
| Q4 24 | — | $215.7M | ||
| Q3 24 | $369.6M | $196.6M | ||
| Q2 24 | $265.8M | $198.6M | ||
| Q1 24 | — | $188.6M |
净利润IGICOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $105.1M | $-22.8M | ||
| Q2 25 | $61.4M | $-14.1M | ||
| Q1 25 | — | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $-134.4M | $-27.4M | ||
| Q2 24 | $70.7M | $-33.4M | ||
| Q1 24 | — | $-36.0M |
毛利率IGICOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率IGICOFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | -8.3% | ||
| Q2 25 | 24.2% | -7.9% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | — | -9.6% | ||
| Q2 24 | -73.3% | -12.5% | ||
| Q1 24 | — | -15.6% |
净利率IGICOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | 26.0% | -11.1% | ||
| Q2 25 | 23.5% | -6.9% | ||
| Q1 25 | — | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | -36.4% | -13.9% | ||
| Q2 24 | 26.6% | -16.8% | ||
| Q1 24 | — | -19.1% |
每股收益（稀释后）IGICOFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $2.31 | $-0.57 | ||
| Q2 25 | $1.36 | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | $1.82 | $-0.71 | ||
| Q2 24 | $1.55 | $-0.88 | ||
| Q1 24 | — | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $244.7M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $654.8M | $450.0M |
| 总资产 | $2.0B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IGICOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | $244.7M | $62.9M | ||
| Q2 25 | $164.8M | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | $219.2M | $30.1M | ||
| Q2 24 | $237.3M | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务IGICOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益IGICOFIX
| Q4 25 | — | $450.0M | ||
| Q3 25 | $654.8M | $442.5M | ||
| Q2 25 | $662.3M | $458.3M | ||
| Q1 25 | — | $458.3M | ||
| Q4 24 | — | $503.1M | ||
| Q3 24 | $540.5M | $525.9M | ||
| Q2 24 | $588.2M | $546.0M | ||
| Q1 24 | — | $570.3M |
总资产IGICOFIX
| Q4 25 | — | $850.6M | ||
| Q3 25 | $2.0B | $832.6M | ||
| Q2 25 | $2.1B | $837.2M | ||
| Q1 25 | — | $823.1M | ||
| Q4 24 | — | $893.3M | ||
| Q3 24 | $1.8B | $867.9M | ||
| Q2 24 | $2.0B | $882.0M | ||
| Q1 24 | — | $906.0M |
负债/权益比IGICOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流IGICOFIX
| Q4 25 | — | $27.7M | ||
| Q3 25 | — | $12.4M | ||
| Q2 25 | $27.2M | $11.6M | ||
| Q1 25 | — | $-18.4M | ||
| Q4 24 | — | $23.7M | ||
| Q3 24 | — | $11.7M | ||
| Q2 24 | $120.7M | $9.0M | ||
| Q1 24 | — | $-18.6M |
自由现金流IGICOFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | $26.8M | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | $119.8M | $-360.0K | ||
| Q1 24 | — | $-29.1M |
自由现金流率IGICOFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | 10.2% | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | 45.1% | -0.2% | ||
| Q1 24 | — | -15.4% |
资本支出强度IGICOFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | 0.2% | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | 0.3% | 4.7% | ||
| Q1 24 | — | 5.6% |
现金转化率IGICOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.44× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.71× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IGIC
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
